Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs JPMorgan Chase & Co — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $296.08 (market cap $8.04B), while JPMorgan Chase & Co trades at $347.85 (market cap $911.47B). The key difference: JPMorgan Chase & Co is far larger — about 113.4× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and JPMorgan Chase & Co pays a 1.75% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | JPM | |
|---|---|---|
Market Cap | $8.04B | $911.47B |
Sector | Health | Financials |
52-Week High | $339.75 | $346.91 |
52-Week Low | $241.71 | $282.84 |
Enterprise Value | $7.85B | — |
Volume | — | 10,479,943 |
Dividend Yield | — | 1.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
JPMorgan Chase (JPM) trades at $342.89, up 2.5% on the day, with a bullish technical outlook and strong analyst support. Recent earnings beat expectations in Q1 and Q2 2026, with revenue growth from $181.85B in 2025 to $186.4B projected for 2026. The stock shows robust fundamentals with a P/E of 14.69 and ROE of 17.03%, though cash flow trends indicate volatility.
The outlook is positive with a consensus price target of $377.75, offering ~10% upside. Risks include geopolitical tensions and cybersecurity threats, but institutional buying and CEO Dimon's leadership provide stability. Investors should weigh earnings consistency against macroeconomic uncertainties for potential gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
